A research report by Certis Oncology Solutions Inc. from the U.S. (“CERTIS”) on a Polish oncology drug candidate indicate that PolEpi may have more potent anti-tumor activity in ovarian cancer than epirubicin hydrochloride, which is currently used in its treatment. Read more at termedia.pl